Evidence map›Paper›PMID 39223656›Full record

ReviewJournal of hematology & oncology2024

Cancer associated fibroblasts and metabolic reprogramming: unraveling the intricate crosstalk in tumor evolution.

Fusheng Zhang, Yongsu Ma, Dongqi Li, Jianlei Wei, Kai Chen, Enkui Zhang, Guangnian Liu, Xiangyu Chu, Xinxin Liu, Weikang Liu and 2 more

Abstract readReview
In one paragraph

Review in Journal of hematology & oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Dual-Target Nectin-4/FAP Heterobivalent ProbeAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  6. Article
  7. Review
  8. Review
  9. Epithelial-mesenchymal transition and cancer-associated fibroblasts in tumor progression and therapy resistance: mechanistic convergence and therapeutic opportunities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. GPX8Oncogene · 2026
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fusheng Zhang *Department of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, Beijing, 100034, China.
Yongsu Ma *Department of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, Beijing, 100034, China.
Dongqi Li *Department of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, Beijing, 100034, China.
Jianlei WeiKey laboratory of Microecology-immune Regulatory Network and Related Diseases School of Basic Medicine, Jiamusi University, Jiamusi, Heilongjiang Province, 154007, China.
Kai ChenDepartment of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, Beijing, 100034, China.
Enkui ZhangDepartment of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, Beijing, 100034, China.
Guangnian LiuDepartment of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, Beijing, 100034, China.
Xiangyu ChuDepartment of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, Beijing, 100034, China.
Xinxin LiuDepartment of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, Beijing, 100034, China.
Weikang LiuDepartment of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, Beijing, 100034, China.
Xiaodong TianDepartment of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, Beijing, 100034, China. tianxiaodong@pkufh.com.
Yinmo YangDepartment of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, Beijing, 100034, China. YangyinmoSCI@bjmu.edu.cn.

Funding

Beijing Municipal Natural Science Foundation 7212111National Key Research and Development Program of China 2021YFA0909900National Natural Science Foundation of China 82171722National Natural Science Foundation of China 82271764
6 · The paper itself

Abstract

Metabolic reprogramming provides tumors with an energy source and biofuel to support their survival in the malignant microenvironment. Extensive research into the intrinsic oncogenic mechanisms of the tumor microenvironment (TME) has established that cancer-associated fibroblast (CAFs) and metabolic reprogramming regulates tumor progression through numerous biological activities, including tumor immunosuppression, chronic inflammation, and ecological niche remodeling. Specifically, immunosuppressive TME formation is promoted and mediators released via CAFs and multiple immune cells that collectively support chronic inflammation, thereby inducing pre-metastatic ecological niche formation, and ultimately driving a vicious cycle of tumor proliferation and metastasis. This review comprehensively explores the process of CAFs and metabolic regulation of the dynamic evolution of tumor-adapted TME, with particular focus on the mechanisms by which CAFs promote the formation of an immunosuppressive microenvironment and support metastasis. Existing findings confirm that multiple components of the TME act cooperatively to accelerate the progression of tumor events. The potential applications and challenges of targeted therapies based on CAFs in the clinical setting are further discussed in the context of advancing research related to CAFs.

Indexed as

Cancer-Associated FibroblastsNeoplasmsTumor MicroenvironmentAnimalsCellular ReprogrammingHumansMetabolic ReprogrammingNeoplasm MetastasisCancer-associated fibroblastsImmune suppressionInflammatory microenvironmentMetabolic reprogrammingTumor metastasisTumor therapy

Identifiers

PMID39223656
PMCPMC11367794

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.